Literature DB >> 8153652

Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: interim analysis of a prospective randomized trial.

N Marschner1, R Kreienberg, R Souchon, U Räth, B Eggeling, R Voigtmann, K Ruffert, M Schütte, A Ammon, T Kesztyüs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8153652

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  7 in total

1.  Dexverapamil to overcome epirubicin resistance in advanced breast cancer.

Authors:  B Thürlimann; N Kröger; J Greiner; K Mross; J Schüller; E Schernhammer; K Schumacher; G Gastl; J Hartlapp; H Kupper
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

Review 2.  A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy.

Authors:  R Abraham; R L Basser; M D Green
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

Review 3.  Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer.

Authors:  A J Coukell; D Faulds
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

4.  Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer.

Authors:  M Lehnert; K Mross; J Schueller; B Thuerlimann; N Kroeger; H Kupper
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

Review 5.  Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy.

Authors:  Elvira C van Dalen; Helena J H van der Pal; Leontien C M Kremer
Journal:  Cochrane Database Syst Rev       Date:  2016-03-03

6.  Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM).

Authors:  G Colucci; S Romito; V Gebbia; G Pacilio; F Giotta; A Testa; G Pezzella; E Durini; B Agostara; S Cariello
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

7.  Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer.

Authors:  F Cappuzzo; F Mazzoni; A Gennari; S Donati; B Salvadori; C Orlandini; G L Cetto; A Molino; E Galligioni; M Mansutti; S Tumolo; A Lucentini; F Valduga; S Bartolini; L Crinò; P F Conte
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.